Skip to content

GRAIL, Inc.

American biotechnology and pharmaceutical company

GRAL Nasdaq SEC CIK 1699031

Follow GRAIL Weekly email: filings, results, news

News

12 stories filed under GRAIL, grouped into ongoing threads

Test

Thread · 4 stories · active today

FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.

Markets 2 h ago 2 sources

This Controversial Cancer Test Just Passed a Key FDA Vote. Here’s Why It’s Dividing Experts

Markets 2 h ago

STAT+: FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks

Markets 1 d ago

Grail rallies as FDA staff flags no major concerns for multi-cancer test

Markets 1 d ago

More coverage

Why is Grail stock surging today?

Markets 12 h ago

This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval

Markets 1 d ago

Grail CFO Aaron Freidin sells $671,579 in company stock

Markets 23 d ago

Grail CEO Joshua Ofman sells $425,098 in company stock

Markets 23 d ago

GRAIL: Looking Beyond The NHS-Galleri Headline

Markets 43 d ago also on NHS

GRAIL at Canaccord Genuity conference: growth meets regulatory test

Policy 44 d ago

STAT+: FDA panel to weigh Grail’s Galleri test

Markets 45 d ago

GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript

Earnings 49 d ago 2 sources

Next results

NOV6

Q2 2026 results

Friday · estimated from the filing cadence

Profile

Headquarters: SUNNYVALE, CA, United States
Founded: 2015
Sector: Healthcare
Industry: Services-Medical Laboratories
Website: grail.com

Peers

Where this page comes from

Profile · SEC EDGAR, Wikidata

Next results · estimated from the filing cadence (SEC EDGAR)

News · 12 stories clustered from the RSS aggregator